BECLOMIN 100 HFA INHALER
BECLOMETASONE DIPROPIONATE
What it does
Beclometasone is a type of corticosteroid used to reduce inflammation in the body.
Commonly used for: asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:03:09 · updated 2026-08-03 04:14:54
Drug Interactions
39Pharmacodynamic Warnings
Beclometasone appears in TABLE 17: Drugs that reduce serum potassium
Severe (1)
Mifamurtide - decreases efficacy
Corticosteroidsarepredictedtodecreasetheefficacyof mifamurtide.Avoid.rTheoretical
Moderate (18)
Corticosteroids - increases exposure
Dronedarone is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - increases concentration
Miconazole is predicted to increase the concentration of corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - increases exposure
Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - decreases exposure
Cenobamate is predicted to decrease the exposure to corticosteroids (fluticasone). Adjust dose.
Corticosteroids - decreases efficacy
Mifepristone is predicted to decrease the efficacy of corticosteroids. Use with caution and adjust dose.
Unknown (20)
Aspirin - decreases concentration
Corticosteroids are predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with corticosteroids.
Beclometasone - increases exposure
Cobicistat is predicted to increase the exposure to corticosteroids (beclometasone) (risk with beclometasone is likely to be lower than with other corticosteroids).
Beclometasone - increases exposure
Idelalisib is predicted to increase the exposure to beclometasone (risk with beclometasone is likely to be lower than with other corticosteroids).
Beclometasone - increases exposure
Clarithromycin is predicted to increase the exposure to corticosteroids (beclometasone) (risk with beclometasone is likely to be lower than with other corticosteroids).
Choline Salicylate - decreases concentration
Corticosteroids are predicted to decrease the concentration of cholinesalicylate. Ciclesonide → see corticosteroids Ciclosporin → see TABLE 2 p. 1517 (nephrotoxicity), TABLE 16 p. 1521 (increased seru
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class
About this medicine
Beclometasone is a type of corticosteroid used to reduce inflammation in the body.
What it treats
- asthma
- allergic rhinitis (hay fever)
- chronic obstructive pulmonary disease (COPD)
How it works
It works by decreasing inflammation and swelling in the airways, making it easier to breathe.
Who it's for
This medication is suitable for people with conditions that involve inflammation, particularly in the lungs and airways.
Drug class
Corticosteroids
Cautions
- • Be careful if you are taking other medications that lower potassium levels in the blood.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: beclometasone
BNF-referencedBeclometasone is a synthetic corticosteroid used primarily for its anti-inflammatory and immunosuppressive properties. It is often administered via inhalation to manage asthma and other respiratory conditions, as well as topically for skin disorders. Beclometasone helps reduce inflammation by inhibiting the release of inflammatory mediators.
Indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Allergic rhinitis
- Topical treatment of inflammatory skin conditions
Dosage
Children: Dosing in children should be determined based on the BNF for Children. Refer to the BNF for specific paediatric dosing information.
Adults: The dosage for adults varies depending on the condition being treated. Refer to the BNF for specific dosing guidelines.
Mechanism of action
Beclometasone acts by binding to glucocorticoid receptors, leading to the modulation of gene expression. This results in the inhibition of pro-inflammatory cytokines and the promotion of anti-inflammatory proteins, thereby reducing inflammation and immune response.
Pharmacodynamics
As a corticosteroid, beclometasone exerts its effects by modulating various cellular functions. It decreases the migration of leukocytes to sites of inflammation, reduces capillary permeability, and inhibits the release of enzymes that contribute to the inflammatory response. The therapeutic effects are evident in conditions characterized by excessive inflammation.
Pharmacokinetics
Beclometasone is well-absorbed when administered by inhalation, and its bioavailability is significantly enhanced when delivered directly to the lungs. It undergoes extensive first-pass metabolism in the liver, which reduces systemic exposure. The half-life of beclometasone is approximately 15 hours, and it is primarily excreted via the urine as metabolites.
Contra-indications
- Hypersensitivity to beclometasone or any of its components
- Systemic fungal infections
- Active or latent tuberculosis
Adverse effects
- Local irritation
- Dryness of the throat
- Cough
- Dysphonia
- Oral candidiasis
- Adrenal suppression (with prolonged use)
Interactions
- cobicistat+beclometasone: Unknown (increases exposure)
- idelalisib+beclometasone: Unknown (increases exposure)
- clarithromycin+beclometasone: Unknown (increases exposure)
Precautions
- Use with caution in patients with active infections
- Monitor for signs of adrenal insufficiency in long-term therapy
- Consider alternate therapy in patients with a history of severe allergic reactions
Pregnancy
Beclometasone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare provider.
Breast-feeding
Beclometasone is excreted in breast milk. Caution should be exercised when administering to nursing mothers.
Storage
Store at room temperature, away from direct sunlight and moisture. Keep out of reach of children.
Formulations
- Inhaler
- Nasal spray
- Topical cream
- Topical ointment
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: Beclometasonedipropionate
BNF-referencedBeclometasone dipropionate is an inhaled corticosteroid used primarily for the prophylaxis and treatment of asthma and other respiratory conditions. It reduces inflammation in the airways, improving breathing in patients with obstructive airway diseases.
Indications
- Prophylaxis of asthma
- Management of allergic rhinitis
- Treatment of nasal polyps
Dosage
Children: For children aged 2–11 years, the dose is 100–200 micrograms twice daily; for children aged 12–17 years, 200–400 micrograms twice daily, adjusted according to response.
Adults: For adults and children over 12 years with chronic asthma, the usual starting dose is 200-400 micrograms twice daily, which may be increased if necessary.
Mechanism of action
Beclometasone dipropionate acts by binding to glucocorticoid receptors in target cells, leading to the modulation of gene expression and the inhibition of pro-inflammatory cytokines, thereby reducing inflammation and hyperresponsiveness in the airways.
Pharmacodynamics
As a potent anti-inflammatory agent, beclometasone dipropionate decreases the infiltration of inflammatory cells into the airways, reduces mucus production, and enhances beta-adrenergic responsiveness. This results in improved airflow and reduced asthma symptoms.
Pharmacokinetics
Beclometasone dipropionate is administered via inhalation, where it undergoes extensive first-pass metabolism in the liver. Its systemic bioavailability is low due to significant hepatic metabolism. The drug has a long duration of action, with effects lasting for 12-24 hours, allowing for once or twice-daily dosing.
Contra-indications
- Hypersensitivity to beclometasone dipropionate or any of its excipients
- Hypersensitivity to atropine or its derivatives
Adverse effects
- Throat irritation
- Wheezing
- Nasal complaints
- Headache
- Nausea
- Stomatitis
- Gastrointestinal absorption may occur
- Corneal oedema
- Eye disorders
- Eye pain
- Palpitations
Precautions
- Monitor growth in children receiving prolonged treatment
- Consider systemic corticosteroid side effects with high doses or prolonged use
Pregnancy
Manufacturer advises only use if potential benefit outweighs the risk.
Breast-feeding
No information available-manufacturer advises only use if potential benefit outweighs risk.
Storage
Store at room temperature, away from moisture and heat.
Formulations
- Inhalation aerosol (Clenil Modulite®)
- Inhalation powder (Qvar®)
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: beclometasone
PubChem CID 20469Molecular formula: C22H29ClO5
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.
- CANDIBIOTIC EAR DROPS · Glenmark Pharmaceuticals
- Candid B · Glenmark Pharmaceuticals
- Candiderm · Glenmark Pharmaceuticals
- DECOMIT 100 INHALATION AEROSOL · Beximco Pharmaceuticals
- Ecodax G · Unique Pharmaceutical Laboratories
- Elyclob G · Elys Chemical Industries